Angiopoietin 2 and Cardiovascular Disease in Dialysis and Kidney Transplantation

American Journal of Kidney Diseases

Volumn 53, Issue 5, 2009, Pages 770-778

  David, Sascha ^a   Kümpers, Philipp ^a   Hellpap, Julian ^a   Horn, Rüdiger ^a   Leitolf, Holger ^a   Haller, Hermann ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Ang 1; Ang 2; Angiopoietin; atherosclerosis; cardiovascular disease (CVD); coronary heart disease (CHD); dialysis; hemodialysis; kidney; peripheral arterial disease (PAD); renal transplantation

Indexed keywords

ANGIOPOIETIN 2; ANGIOTENSIN I;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; IMMUNORADIOMETRIC ASSAY; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOPSY; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; INCIDENCE; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 64749097050     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.11.030     Document Type: Article

References (44)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007) 2038-2047
2. Sarnak M.J. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 41 (2003) 11-17
3. Kilpatrick R.D., McAllister C.J., Kovesdy C.P., et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18 (2007) 293-303
4. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10 (1999) 594-600
5. Kielstein J.T., and Zoccali C. Asymmetric dimethylarginine: A cardiovascular risk factor and a uremic toxin coming of age?. Am J Kidney Dis 46 (2005) 186-202
6. Caglar K., Yilmaz M.I., Saglam M., et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 3 (2008) 61-68
7. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358 (2001) 2113-2117
8. Roberts M.A., Hare D.L., Ratnaike S., and Ierino F.L. Cardiovascular biomarkers in CKD: Pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 48 (2006) 341-360
9. Fam N.P., Verma S., Kutryk M., and Stewart D.J. Clinician guide to angiogenesis. Circulation 108 (2003) 2613-2618
10. Brindle N.P., Saharinen P., and Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 98 (2006) 1014-1023
11. Fiedler U., and Augustin H.G. Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol 27 (2006) 552-558
12. Kim I., Kim H.G., So J.N., et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ Res 86 (2000) 24-29
13. Findley C.M., Cudmore M.J., Ahmed A., and Kontos C.D. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 27 (2007) 2619-2626
14. Thurston G., Rudge J.S., Ioffe E., et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6 (2000) 460-463
15. Witzenbichler B., Westermann D., Knueppel S., Schultheiss H.P., and Tschope C. Protective role of angiopoietin-1 in endotoxic shock. Circulation 111 (2005) 97-105
16. Lim H.S., Lip G.Y., and Blann A.D. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: Relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180 (2005) 113-118
17. Nykanen A.I., Krebs R., Saaristo A., et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107 (2003) 1308-1314
18. Lee K.W., Lip G.Y., and Blann A.D. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor Tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110 (2004) 2355-2360
19. Parikh S.M., Mammoto T., Schultz A., et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 3 (2006) e46
20. Yuan H.T., Tipping P.G., Li X.Z., Long D.A., and Woolf A.S. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int 61 (2002) 2078-2089
21. Davis B., Dei Cas A., Long D.A., et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol 18 (2007) 2320-2329
22. Post S., Peeters W., Busser E., et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 45 (2008) 244-250
23. Schwarz A., Mengel M., Gwinner W., et al. Protocol biopsy program after renal transplantation: Structure and first results. Transplant Proc 34 (2002) 2238-2239
24. Kumpers P., Koenecke C., Hecker H., et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 112 (2008) 2139-2148
25. Lukasz A., Hellpap J., Horn R., et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: Development and clinical application of two new immunoassays. Crit Care 12 (2008) R94
26. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
27. Weibel E.R., and Palade G.E. New cytoplasmic components in arterial endothelia. J Cell Biol 23 (1964) 101-112
28. Fiedler U., Scharpfenecker M., Koidl S., et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103 (2004) 4150-4156
29. Pinsky D.J., Naka Y., Liao H., et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 97 (1996) 493-500
30. Reidy M.A., Chopek M., Chao S., McDonald T., and Schwartz S.M. Injury induces increase of von Willebrand factor in rat endothelial cells. Am J Pathol 134 (1989) 857-864
31. Schmidt R.J., and Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 58 (2000) 1261-1266
32. Matsushita K., Morrell C.N., Cambien B., et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 115 (2003) 139-150
33. Yao D., Taguchi T., Matsumura T., et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282 (2007) 31038-31045
34. Fiedler U., Reiss Y., Scharpfenecker M., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12 (2006) 235-239
35. Goettsch W., Gryczka C., Korff T., et al. Flow-dependent regulation of angiopoietin-2. J Cell Physiol 214 (2008) 491-503
36. Aicher A., Zeiher A.M., and Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 45 (2005) 321-325
37. Haller H., de Groot K., Bahlmann F., Elger M., and Fliser D. Stem cells and progenitor cells in renal disease. Kidney Int 68 (2005) 1932-1936
38. Davis S., Papadopoulos N., Aldrich T.H., et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 10 (2003) 38-44
39. Rondaij M.G., Bierings R., Kragt A., van Mourik J.A., and Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 26 (2006) 1002-1007
40. Boulanger C.M., Amabile N., Guerin A.P., et al. In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension 49 (2007) 902-908
41. Tressel S.L., Huang R.P., Tomsen N., and Jo H. Laminar shear inhibits tubule formation and migration of endothelial cells by an angiopoietin-2 dependent mechanism. Arterioscler Thromb Vasc Biol 27 (2007) 2150-2156
42. Kanazawa H., Nomura S., and Asai K. Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients. Chest 131 (2007) 1035-1041
43. Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6 (2004) 507-516
44. Tressel S.L., Kim H., Ni C.W., et al. Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis. Arterioscler Thromb Vasc Biol 28 (2008) 1989-1995